Free-cash-flow proxy increased 84.0%
Free-cash-flow proxy changed +84.0% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
$108.3M→$199.3M6 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →MDB financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating cash flow increased 83.4%
Operating cash flow changed +83.4% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
$109.9M→$201.6M6 prior comparisons
Operating margin moved 615 bp higher
Operating margin changed +615 basis points from the comparable as-filed period.
-9.75%→-3.61%3 prior comparisons
Operating income increased 53.7%
Operating income changed +53.7% from the comparable as-filed period.
-$53.6M→-$24.8M3 prior comparisons
Revenue increased 25.2%
Revenue changed +25.2% from the comparable as-filed period.
$549.0M→$687.6M3 prior comparisons
Cash & equivalents increased 57.5%
Cash & equivalents changed +57.5% from the comparable as-filed period.
$657.8M→$1.0B2 prior comparisons
SBC / revenue moved 408 bp lower
SBC / revenue changed -408 basis points from the comparable as-filed period.
24.12%→20.04%3 prior comparisons
Gross profit increased 26.9%
Gross profit changed +26.9% from the comparable as-filed period.
$391.0M→$496.2M3 prior comparisons
Gross margin moved 95 bp higher
Gross margin changed +95 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
71.21%→72.16%3 prior comparisons
Research & development increased 18.7%
Research & development changed +18.7% from the comparable as-filed period.
$168.8M→$200.4M3 prior comparisons
Net income changed across a sign change
Net income changed +111.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
-$37.6M→$4.4M2 prior comparisons
Capital expenditure increased 43.9%
Capital expenditure changed +43.9% from the comparable as-filed period. The change ranks at the 33th percentile of 6 prior comparable changes.
$1.6M→$2.3M6 prior comparisons
Capex / revenue moved 4 bp higher
Capex / revenue changed +4 basis points from the comparable as-filed period.
0.29%→0.34%2 prior comparisons
Stock-based compensation increased 4.1%
Stock-based compensation changed +4.1% from the comparable as-filed period.
$132.4M→$137.8M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.